Drug Dealin' Podcast | Ep. 6: Should the FDA Be Independent?

Watch now | SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA.

Sep 9 • 

Big Pharma Sharma

1

1:41:59

August 2025

The In Vivo Gold Rush: Big Pharma's $3B Cell Therapy Bet

Why Kite's entry into in vivo cell therapy marks a pivotal moment for an industry seeking to overcome the cost and scalability challenges of autologous…

Aug 22 • 

Big Pharma Sharma

3

Moderna's Oncology Inflection Point: When Platform Dreams Meet Strategic Reality

Heads up, reader!

Aug 5 • 

Big Pharma Sharma

1

July 2025

Changing of the Guard at AbbVie: New Leadership = New Strategy

AbbVie has done a few deals under new CEO, Rob Michael, and these deals could signal a major shift in strategy from the Rick Gonzalez era

Jul 16 • 

Big Pharma Sharma

1

Drug Dealin' Ep. 5: How to Talk to Doctors | Feat. Joe McCann, Co-Founder/CEO of Slingshot Insights

Kenny and I talk to Joe McCann about how to prepare for, ask questions, and get more out of your engagements with doctors, whether you're an investor…

Jul 1 • 

Big Pharma Sharma

1

1:41:28

June 2025

Speed, Scale, and Shifting Goal-Posts: What ASCO 2025’s Spotlight Trials Really Mean for the Next Wave of Oncology Players

Discussing a few interesting solid tumor data read outs to close out ASCO 2025 coverage

Jun 17 • 

Big Pharma Sharma

2

1

ASCO 2025: Bicara vs. Merus in a Set-to-Change Head & Neck Cancer Treatment Paradigm

While Bicara took a hit after Merus released its ASCO data, there is strong reason to believe that Bicara could end up coming out on top in the end

Jun 8 • 

Big Pharma Sharma

2

ASCO25: Ivonescimab Dis-HARMONi, is it a Rabbit or a Duck?

Plus, new data from Pfizer’s $1.25B PD-1xVEGF and what all this says about Summit's lead in the highly competitive PD-1xVEGF space

Jun 2 • 

Big Pharma Sharma

1

May 2025

Drug Dealin' Ep.4: Ozempic for the Brain, A New Era to Explain

Summary: In this episode, Shivu and Kenny delve into the evolving landscape of GLP-1 drugs, particularly focusing on the recent advancements in oral…

May 19 • 

Big Pharma Sharma

2

54:59

Vinay Prasad at CBER: What His Appointment Signals for the Future of Biotech Regulation

Potential implications of the Prasad appointment and some early evidence that maybe it's not all doom-and-gloom? I guess we'll find out soon enough…

May 9 • 

Big Pharma Sharma

April 2025

What 2025 Holds for GLP-1s in Brain Health

It feels like every year is “the year of the GLP‑1,” but 2025 may really be the one where we crack how these drugs work in the brain—far beyond weight…

Apr 17 • 

Big Pharma Sharma

3

March 2025

Biotech Czar for a Day: An Abundance Agenda for Biotech

A thought experiment on how we can make our Biotech ecosystem more abundant

Mar 31 • 

Big Pharma Sharma

5